About
Nocions which preferentially target activated sensory neurons that are responding to external insult
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Team (5)
James L. Ellis, Ph.D.
Chief Scientific Officer
Nocion Therapeutics
executive
Joan E. Shaw, MT, MS(SCC)
Senior Vice President, Clinical Operations
Nocion Therapeutics
executive
Matthew Frankel, M.D., MBA
Chief Medical Officer
Nocion Therapeutics
executive
Peter Courossi
Acting Chief Financial Officer
Nocion Therapeutics
executive
Richard P. Batycky, Ph.D.
President and Chief Executive Officer
Nocion Therapeutics
executive
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
479
By Phase
PHASE2: 1PHASE1: 1
By Status
RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06504446Lead Sponsor
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
PHASE2Recruiting
455 participants
Started: Sep 24, 2024 · Completed: Nov 10, 2025
NCT05628740Lead Sponsor
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
PHASE1Completed
24 participants
Started: Feb 7, 2022 · Completed: Oct 25, 2022
Locations (1)
Headquarters
Watertown, MA, United States
Map
Loading map...